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Background: Gut microbial diversity and composition play important roles in health.
This cross-sectional study was designed to test the hypothesis that hospitalized children
who may be relatively immunocompromised (IC), defined as those with cancer, sickle
cell disease (SCD), transplantation, or receiving immunosuppressive therapy) would have
decreased microbial diversity, increased Clostridioides difficile colonization and different
species composition compared to non-immunocompromised (Non-IC) children admitted
to the same pediatric unit.
Methods: A stool sample was obtained within 72 h of admission to a single unit at The
Children’s Hospital at Montefiore, Bronx, NY from March 2016 to February 2017 and the
microbiome assessed by 16S rRNA sequencing. C. difficile colonization was assessed
by glutamate dehydrogenase antigen and toxin polymerase chain reaction assays.
Results: Stool samples were obtained from 69 IC (32 SCD, 19 cancer, 9 transplantation
and 9 other) and 37 Non-IC patients. There were no significant differences in microbial
alpha diversity and C. difficile colonization comparing IC vs. non-IC patients. Lower alpha
diversity, however, was independently associated with the use of proton pump inhibitors
or antibiotics, including prophylactic penicillin in patients with SCD. Differences in specific
species abundances were observed when comparing IC vs. non-IC patients, particularly
children with SCD. Non-IC patients had increased abundance of commensals associated
with health including Alistipes putredinis, Alistipes ihumii, Roseburia inulinivorans,
Roseburia intestinalis, and Ruminococcus albus (p < 0.005).
Conclusions: Antibiotics and proton pump inhibitors, which were more commonly
used in IC children, were identified as risk factors for lower microbial diversity. Non-
IC patients had higher abundance of several bacterial species associated with health.
Longitudinal studies are needed to determine the clinical significance of these differences
in gut microbiome.
Keywords: microbiome, clostridioides difficile, sickle cell disease, dysbiosis, immunocompromised and healthy
subjects
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INTRODUCTION
The gastrointestinal (GI) microbiome is comprised of a highly
diverse community of bacteria, fungi, protozoa and viruses
that play critical roles in physiology, metabolism, health, and
disease. More than 1014 microorganisms may be found in the
intestine and the composition and diversity are impacted by
diet, exposure to antibiotics and other environmental factors.
Six bacterial phyla (Firmicutes, Proteobacteria, Bacteroidetes,
Fusobacteria, Actinobacteria, andVerrucomicrobia) dominate the
gut of healthy adults (1). Changes in microbial composition are
associated with immune dysregulation and have been linked to
multiple diseases including inflammatory bowel disease (IBD),
obesity, autoimmune diseases, cancer, and infections (2–5). A
loss of diversity may promote growth of pathogenic bacteria
including toxin-producing Clostridioides (C.) difficile (6).
Maintenance of gut microbial diversity may prevent
colonization and/or overgrowth of pathogenic bacteria by
several mechanisms. For example, commensal bacteria may
promote epithelial cells to produce antimicrobial peptides,
which can inhibit growth of pathogens and reduce the risk of
bacterial translocation from the gut to the systemic circulation
(7). An increase in Enterococci or Enterobacteriaceae and a
concomitant decrease in commensal anaerobic microbiota
in the stool are associated with a significantly increased risk
of bloodstream infections with the same bacterial species in
hematopoietic cellular transplant (HCT) and cancer patients (8).
These findings have led to speculation that real-time monitoring
of the gut microbiome in IC populations may be of value in
identifying patients at increased risk for future bacteremia
and selecting empiric therapy pending culture identification.
The gut microbiome may also influence response to cancer
immunotherapies, engraftment following transplantation, and
risk of graft-vs.-host disease (9, 10).
There are fewer studies evaluating the microbiome in
pediatric patients and, specifically, at the time of hospitalization,
and no studies comparing immunocompromised (IC) and
non- immunocompromised (non-IC) children. To address this
knowledge gap, we conducted a cross-sectional study of the gut
microbiome in children admitted to a single unit in a pediatric
hospital over a 1 year period to test the hypothesis that “IC”
children, defined as those with diseases associated with immune
suppression including cancer, HCT, solid organ transplantation
(SOT) and sickle cell disease (SCD), would have decreased
microbial diversity as well as higher rates of asymptomatic
C. difficile colonization, a biomarker of decreased diversity,
compared to non-IC children hospitalized on the same unit.
These differences could contribute to adverse outcomes.
METHODS
Study Population
The study was conducted on a single inpatient unit at the
Children’s Hospital of Montefiore in Bronx, New York, from
March 2016 to February 2017. The unit includes patients with
cancer, SCD, and HCT or SOT recipients. Low infectious risk
patients are also hospitalized on this unit. The Albert Einstein
College of Medicine-Montefiore Institutional Review Board
approved the study.
All patients < 22 years of age were invited to participate
in the study. Patients were excluded if they had C. difficile
infection currently or within the preceding 2 months or had
been previously enrolled in the study on a prior admission. The
electronic medical record was reviewed for demographic data,
medical and surgical history, prior hospitalizations, history of
diarrhea including C. difficile colitis, antibiotic exposures within
the previous 3 months, and other medications. Participants were
requested to provide a stool sample within 72 h of admission.
Stool samples were transported to the laboratory, immediately
refrigerated, and subsequently divided into aliquots within 48 h
and stored at−70◦C.
Sequencing of Bacterial 16S rRNA Gene
Metagenomic DNA was extracted from stool samples using
a PowerSoil R© DNA Isolation Kit (11). The V1 through V3
hyper-variable regions (V1-V3) of 16S rRNA genes were
amplified from the metagenomic DNA using primers 27F
and 534R (27F: 5’- AGAGTTTGATCCTGGCTCAG-3′ and
534R: 5’-ATTACCGCGGCTGCTGG-3′). The oligonucleotides
containing the 16S primer sequences also contained an adaptor
sequence for Illumina MiSeq platform as well as one of 240 tag
sequences unique to each sample. A barcode sequence unique to
each sample is embedded within each of the forward and reverse
oligonucleotides used to create the amplicons (dual tags). The
uniquely barcoded amplicons frommultiple samples were pooled
and sequenced on the Illumina MiSeq sequencing platform
using a V3 2 × 300 sequencing protocol. Illumina’s software
was used for initial processing of all the raw sequencing data.
One mismatch in primer and zero mismatch in barcodes are
applied to assign read pairs to the appropriate sample within
a pool of samples. Barcode and primers were removed from
the reads. Reads were further processed by removing primers
using Trimmomatic v0.32 with the commands HEADCROP:20,
TRAILING:10, MINLEN:100 (12) joining paired-end sequences
using the FLASH algorithm (13) and removing chimeric
sequences with UChime (14). The cleaned, assembled amplicons
were the input data for analysis.
C. difficile Testing
Samples were batched and analyzed for C. difficile glutamate
dehydrogenase (GDH) and toxin A/B by enzyme immunoassay
(EIA) (C. diff quik chek complete R© Techlab) followed by toxin
B PCR. (Xpert R© C. difficile/ Epi). Colonization was defined as
having a positive stool GDH assay; toxigenic colonization was
defined as positive GDH plus a positive EIA or toxin B PCR assay
in patients without diarrhea.
Statistical Methodology
Metadata analyses were performed using Stata/SE 14.2 and
Graphpad Prism (version 7). Chi-square test of association
with the Pearson value was used to compare categorical
variables between IC and non-IC patients and subpopulations.
Logistic regression was used to calculate odds ratios. Multiple
comparative analyses were performed using the Tukey’s multiple
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comparisons test. All P values were 2-sided and used a 5% level
of significance.
A sampling average depth of about 37,600 reads per sample
of a total of 104 samples was used for microbiome downstream
analysis using Phyloseq package (15). The Shannon Diversity
Index was calculated as Σ piln(pi), where pi presents the
proportional abundance of species. The non-parametric
Wilcoxon and Kruskal-Wallis rank sum-tests were used for
differential diversity or abundance between two or more
groups, respectively, and corrected for multiple comparisons
by Benjamini-Hochberg procedure. Beta diversity was analyzed
using the Bray-Curtis distance for community abundance
and Jaccard distance for community presence/absence.
The among-group differences were determined using the
permutational multivariate analysis of variance by the distance
matrices (ADONIS) and the analysis of group similarities
(ANOSIM). These tests compare the intragroup distances to
the intergroup distances in a permutation scheme and then
calculate a p-value. These functions are implemented in the
Vegan package (16). For all permutation tests, we used 999
permutations by default setting in the Vegan package.
Random forest package was used to predict operational
taxonomic units (OTUs) that differentiated groups. Based
on the construction of multiple decision trees according to
the bagging approach, each tree was built independently
from a boostrap sampling. Using the mean decrease accuracy
criterion, the classification was performed and identified the
most reliable and relevant OTUs, this method ranks factors
based on their ability to distinguish different groups by
considering the complex interrelationship within a group.
Principal coordinate analysis (PCoA) plots, boxplots and
heatmaps were generated for graphical analysis by using
Phyloseq, ggplot2 and ComplexHeatmap packages, respectively.
RESULTS
Clinical and Demographic Features of
Study Population
During the 12-month study period, 106 unique patients who
met inclusion criteria provided a stool sample within 72 h of
admission. Sixty-nine patients were classified as IC, including
19 with cancer, 32 with SCD, 3 HCT and 6 SOT recipients (4
liver and 2 renal), and 9 with other chronic illnesses associated
with immune suppression. Thirty-seven patients were classified
as non-IC (Supplementary Table 1). Clinical and demographic
data are summarized in Table 1. Age of patients ranged from 0.01
to 20.84 years with a mean of 6.07 years. There was a trend for
the IC cohort (mean age 5.71 years) to be older than the non-
IC cohort (mean age 4.65 years) (p = 0.06). The IC patients
were significantly more likely to be currently receiving antibiotics
(p = 0.02), have received antibiotics within the last 3 months
(p < 0.001) and to have had at least one prior hospitalization
within the previous 3 months (p = 0.008). IC patients were also
significantly more likely to be receiving a proton pump inhibitor
(PPI) (p = 0.02) (Table 1). There were no differences in C.
TABLE 1 | Demographics and clinical characteristics of participants.
IC (n = 69) Non IC (n = 37) P-value
Age in years [mean (SD)] 8.3 (5.71) 4.65 (5.69) 0.06




Antibiotics in last 3 months
[n (%)]
43 (62%) 9 (24%) <0.001
Antibiotics during current
admission [n (%)]
49 (71%) 18 (48%) 0.02
Hospitalization within last 3
months [n (%)]
33 (48%) 8 (22%) 0.008
Proton pump inhibitor use 15 (22%) 2 (5%) 0.02
C. difficile colonization
(GDH) [n (%)]
16 (23%) 7 (19%) 0.61
Toxin B + C. difficile by PCR
[n (%)]
9/16 (56%) 5/7 (71%) 0.58
difficile colonization rates between the IC and non-IC cohorts.
The majority of colonizing isolates were toxin B positive.
Differences in Microbial Diversity and
Predominant Species
16s rRNA sequencing was successfully completed in 104
participants; one non-IC participant did not have an available
aliquot and one IC (SCD) sample was excluded due to
poor DNA quality. Pie charts of the top 8 genera identified
demonstrate that Bacteroides dominated overall (Figure 1).
There were no significant differences in alpha diversity measured
by species richness or evenness (Shannon index) comparing
the IC and non-IC groups (Figures 2A,B). However, within the
total population studied, current antibiotics and PPI use were
associated with significantly lower species richness and evenness
(Figures 3A,B). There was also a non-significant trend toward
lower species richness and evenness in those who were colonized
with C. difficile (Figure 3C).
Group dissimilarities were measured by Bray-Curtis distance
considering abundance of OTUs, and by Jaccard distance
assessing community membership. The overall dissimilarity
did not differ between the IC and non-IC groups. However,
association between variation in gut microbiota and host
characteristics using these distances by Anosim (Table 2) and
Adonis (Table 3), respectively, showed that gender (p= 0.03 and
p = 0.039), diarrhea (p = 0.028 and p = 0.013) and PPI use (p
= 0.003 and p = 0.01) were significantly associated with the gut
community bacterial variation (Bray-Curtis distance). Current
antibiotic use was associated with significant effects on microbial
variation (p = 0.002, Adonis) and PPI use was associated with a
significant effect on microbiome membership (Jaccard distance)
in both Anosim and Adonis (p= 0.01 and p= 0.002).
Variable regions one through three (V1-V3) of the 16S rRNA
gene are generally sufficient to identify taxa down to the genus
level and sometimes to the species level; the closest taxonomic
identification based on OTU were identified and compared.
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FIGURE 1 | Pie charts represent total percentage read counts in the IC and non-IC groups for the corresponding color-coded genera with major genera including
Bacteroides, Prevotella, Parabacteroides, Faecalibacterium, Lachnospiracea_incertae_sedis, Veillonella, Klebsiella, Allistipes. Other minor genera were regrouped as
“rare bacteria comprising 1–2%” and “rare bacteria comprising < 1%” of total read counts.
FIGURE 2 | Comparison of (A) species richness (OTU count) and (B) diversity (Shannon index) comparing the IC (n = 69) and non-IC (n = 37) groups. Each point
represents an individual patient and the boxplot shows the median, the first and third quartiles (bottom and top bars of the boxplot) and minimum and maximum
values.
Granulicatella adjacens (OTU 29) was more abundant in IC
patients (p= 0.022), whereas Roseburia inulinivorans (OTU 165)
(p= 0.001), Roseburia intestinalis (OTU 96) (p= 0.001),Alistipes
ihumi (OTU 201) (p = 0.006), Alistipes putredinis (OTU 152) (p
= 0.0099) and Ruminococcus albus (OTU 126) (p= 0.0004) were
more abundant in non-IC patients (Figure 4).
Dominance of OTUs also differed when comparing
participants based on PPI or antibiotic exposure. Streptococcus
parasanguinis (OTU 55) abundance was significantly higher in
those on PPI compared to those not using PPI (p = 0.0027).
Conversely, Eubacterium rectale (OTU 35) (p = 0.0083),
Faecalibacterium prausnitzii (OTU 38) (p = 0.047), Anaerostipes
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FIGURE 3 | Comparison of species richness (left panel) and Shannon index (right panel) in total cohort based on receipt of (A) current antibiotics, (B) proton pump
inhibitors (PPI) over the past 3 months, and (C) C. difficile colonization. ****p < 0.0001, ***p < 0.001, *p < 0.05, ns, not significant; Wilcoxon rank sum test.
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hadrus (OTU 19) (p = 0.029), and Eggerthella lenta (OTU 131)(p
= 0.0002) were more abundant and more prevalent in patients
who were not on PPI (Supplementary Figure 1). Bacteroides
faecis (OTU6) (p = 0.0076), Paraprevotella clara (OTU86)
(p = 0.012), Faecalicatena fissicatena (OTU120) (p = 0.012)
and Roseburia inulinivorans (OTU165) (p = 0.038) were more
abundant in the patients who currently did not use antibiotics
(Supplementary Figure 2). The bacteria significantly affected by
antibiotics were different than those significantly affected by PPI.
C. difficile Colonization
Prior studies suggest that colonization with C. difficile,
specifically, toxigenic strains, is associated with decreased
microbial diversity (17). Overall, 23/106 (22%) of the study
participants were colonized with C. difficile (GDH assay) and the
majority of these (14/23, 61%) were toxin B positive by PCR assay
TABLE 2 | Analysis of similarities (ANOSIM) at the OTU level using Bray-Curtis
distance and Jaccard distance to assess the similarity of bacterial communities
between groups at OTU level.
OTUs Level (relative abundance rarefied)
Variable D_Bray dissimilarity D_Jaccard presence/absence
Ra p-value Ra p-value
IC/Non IC −0.035 0.84 0.0009 0.46
C. difficile −0.013 0.55 0.04 0.26
Gender 0.03 0.03* 0.01 0.13
Abx.last 3m −0.007 0.75 0.009 0.15
Abx.current −0.08 1 0.01 0.31
Diarrhea 0.18 0.028* 0.13 0.085
Hospitalization 0.04 0.077 0.06 0.026*
PPI 0.27 0.003** 0.19 0.01*
aCorrelation coefficient correlation coefficient. *P ≤ 0.05; **P ≤ 0.01.
(Table 1). Colonization with C. difficile or specifically, toxin B+
C. difficile, did not differ comparing the IC vs. non-IC patients,
or within the IC group, comparing the different subgroups. As
expected, colonization was higher in children younger than 1
year of age (6/15, 40%) compared to older children (17/91, 19%)
(Table 4). Non-IC, C. difficile colonized patients had significantly
lower alpha diversity compared to non-IC, non-colonized
patients (p < 0.01) and compared to the IC C. difficile-colonized
group (p= <0.01) (Figure 5).
Being colonized with C. difficile was associated
with specific taxa, including increased proportions of
Peptoclostridium difficile (p = 5e-05), Clostridium spiroforme
(p = 0.064) and Christensenella massiliensis (p = 0.009)
(Supplementary Figure 3). Roseburia inulinivorans (OTU
165) (p = 4.7e-05) and Roseburia intestinalis (OTU 96) (p =
0.002) were more abundant in non-IC, C. difficile-negative
participants compared to IC or C. difficile-colonized patients
(Supplementary Figure 4).
Microbiome in the Subset of Children With
SCD
Children with SCD, comprised the largest subgroup of the IC
cohort. Comparison of this subgroup to the rest of the IC cohort
and the non-IC cohort showed no significant differences in alpha
diversity measured by species richness or evenness (Shannon
index) (Supplementary Figure 5). The subgroup with SCD
also did not differ in beta diversity (Supplementary Figure 6).
However, within the SCD subset, penicillin prophylaxis was
associated with a trend toward a decrease in alpha diversity (p
= 0.11) (data not shown). Patients with SCD receiving penicillin
prophylaxis had a greater abundance of Bacteroides fragilis (p =
0.035) and a lower abundance of Bacteroides xylanisolvens (p =
0.013),C. spiroforme (p= 0.0026), and Blautia obeum (p= 0.052)
compared to SCD patients who were not receiving penicillin
(Supplementary Figure 7). Approximately half of SCD patients
were receiving hydroxyurea (16/32), which did not appear
to have an impact on the bacterial composition or diversity.
TABLE 3 | Adonis analysis assessing association between variation in gut microbiota at OTU level and host characteristics using Bray-Curtis distance and Jaccard
distance.
OTUs Level (relative abundance rarefied)
Variable D_Bray D_Jaccard
F. modela R2b p-value F. model R2 p-value
IC/Non IC 1.03 0.01 0.41 1.18 0.011 0.16
C. difficile 1.28 0.013 0.082 2.34 0.022 0.001**
Gender 1.56 0.015 0.039* 1.22 0.012 0.12
Antibiotics (previous 3 mos.) 0.76 0.007 0.8 1.18 0.011 0.17
Current antibiotics 2.21 0.02 0.002** 3.44 0.033 0.001**
Diarrhea 1.89 0.018 0.013* 1.59 0.015 0.016*
Hospitalization 0.95 0.009 0.49 1.4 0.014 0.038*
PPI 1.95 0.019 0.01* 2.12 0.02 0.002**
aThe pseudo F ratio compares the total sum of squared dissimilarities among subjects between groups to that of subjects within group; large F-ratios indicate strong group separation.
bR2 value indicates the percentage of variation in the group dissimilarities explained by the variable. *P ≤ 0.05; **P ≤ 0.01.
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FIGURE 4 | Specific species that differentiate the community composition between IC and non-IC patients identified by Random Forest plots: Granulicatella adjacens,
Roseburia inulinivorans, Roseburia intestinalis, Alistipes ihumi, Alistipes putredinis, and Ruminococcus albus. ***p < 0.001, **p < 0.01, *p < 0.05, Wilcoxon rank sum
test.
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TABLE 4 | C. difficile GDH and toxin B + colonization in different subgroups of
patients.
Group Any C. difficile [GDH,
n (%)]
Toxin B PCR + (% of total
C. difficile)
Age < 1 year 6/15 (40) 4/6 (67)
Age > 1 year 17/91 (19) 10/17(59)
Cancer 5/19 (26) 3/5 (60%)
Post-transplantation 2/9 (22) 0
SCD 8/32 (25) 6/8 (75%)
Penicillin ppx 7/21 (33) 5/7 (71%)
No penicillin ppx 1/11 (9) 1/1 (100%)
Notably, children with SCD receiving penicillin prophylaxis had
the highest overall rate of colonization with C. difficile (33%)
(Table 4).
DISCUSSION
Both measures of alpha diversity, species richness and evenness
of distribution, were significantly lower in stool samples obtained
from children within 72 h of hospitalization who were receiving
antibiotics or PPIs. These features were found significantly more
often in the population defined as IC compared to non-IC,
although there were no statistically significant differences in
either measure of microbial alpha diversity comparing these two
groups. Thismay reflect the overall heterogeneity of both cohorts.
The non-IC patients, however, did have higher proportions
of several bacterial species that have been associated with
health including Lachnospiraceae (Roseburia inulinivorans and
Roseburia intestinalis) Ruminococcaceae (Ruminococcus albus)
and Rikenellaceae (Alistipes ihumi and Alistipes putredinis).
For example, Roseburia intestinalis metabolize dietary fibers
and produce major short-chain fatty acids, providing energy
sources for enterocytes and achieving anti-inflammatory effects
in the gut. The abundance of R. inulivorans and other butyrate
producers has been shown to be decreased in patients with
IBD compared to healthy controls (18). Ruminococcus albus is
an anaerobic bacterium that produces acetate, ethanol, formate,
hydrogen and carbon dioxide from carbohydrates. Hydrogen-
producing Ruminococcus albus is more abundant in healthy
individuals than in patients with Crohn’s disease (19) and has
probiotic effects (20). Similarly, Alistipes species characterize a
healthy gut microbiome and a recent study of newly diagnosed
pediatric patients with IBD or Crohn’s disease found that IBD
was characterized by decreased abundance of Alistipes finegoldii
and Alistipes putredinis (21).
The observation that current antibiotic use is associated
with decreased diversity is consistent with numerous studies
in the literature (22–25). We also observed that within the
subgroup of IC patients with SCD, those on penicillin prophylaxis
trended toward having lower alpha diversity, higher rates
of asymptomatic C. difficile colonization, and differences in
proportions of select bacteria. Specifically, SCD patients receiving
penicillin had a lower proportion of Lachnospiraceae, a family
of probiotic, anaerobic bacteria, including Blautia obeum and
Bacteroides xylanisolvens. These bacteria play a major role in
the fermentation and degradation of plant fibers, producing
short-chain fatty acids with potential health-beneficial effects
and may also possess immunomodulatory properties (26). These
differences in microbiome among children with SCD receiving
penicillin prophylaxis may also be impacted by age since
prophylaxis is typically prescribed only in children younger than
5 years. SCD patients on penicillin were significantly younger
(mean ± SEM 3.9 ± 0.93 years) than those not on penicillin
(mean ± SEM 9.69 ± 0.89 years) (p <0.007), but age-adjusted
analysis could not be performed in the current study due to the
small sample size.
Few studies have described the microbiome in patients with
SCD. Microbial dysbiosis has been described in two small studies
of adults with SCD (27, 28) and in one was associated with
higher lactate dehydrogenase levels, which may be a biomarker
of ongoing hemolysis (28). However, the link between the
gut microbiome and SCD is complex. For example, depletion
of microbiota with broad-spectrum antibiotics reduced the
number of aged neutrophils and protected against organ damage
in a murine model of SCD (29). Thus, further studies are
needed to determine the clinical implications of changes in gut
microbiome associated with SCD and with penicillin prophylaxis
in this population.
PPIs were also associated with significant decreases in alpha
diversity and microbial composition (beta diversity). Concerns
for PPI use and its effect on the gut microbiome and risk for
C. difficile colitis have been raised in recent years (30–33) but
the effects on microbial diversity and, specifically, in pediatric
patients have not been well-studies. A recent Japanese study
comparing 36 adults taking PPI vs. 36 healthy controls found no
differences in alpha diversity but did find differences in microbial
composition; Streptococcus was significantly more abundant and
Faecalibacterium significantly decreased in PPI users (34). In a
larger adult twin study, PPI use was associated with decreased
alpha diversity and increases in Streptococcaceae and other
oral or upper GI tract flora, suggesting that removal of the
low pH barrier between the upper and lower tract contributes
to the observed differences (31). We also observed significant
increases in Streptococcus parasanguinis and decreases not only
in Faecalibacterium prausnitzi, but also in Eubacterium rectale,
Anaerostipes hadrus and Eggerthella lenta in our cohort of PPI
users. However, the clinical consequences of these microbial
composition differences require further study.
Nearly one-quarter of hospitalized pediatric patients were
found to have asymptomatic C. difficile colonization and
the majority of these were toxin B+, only by PCR; none
were EIA positive. This phenotype (GDH-positive, EIA toxin-
negative, PCR+) is well-described in studies of colitis, but not
colonization, and is associated with less severe disease and fewer
recurrences compared to patients who have colitis associated
with EIA toxin + isolates (35). Antibiotic and PPI use have
been shown to be risk factors for C. difficile infection in children
(36). However, there are relatively fewer studies on colonization.
Consistent with prior studies, C. difficile colonization was
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FIGURE 5 | Comparison of (A) species richness (OTU count) and (B) diversity (Shannon index) comparing the IC and non-IC groups based on C. difficile colonization.
Each point represents an individual patient and the boxplot shows the median, the first and third quartiles (bottom and top bars of the boxplot) and minimum and
maximum values. **p < 0.01, *p < 0.05, ns, not significant; Wilcoxon rank sum test.
positively associated with younger age and with recent antibiotic
exposure (37, 38). Colonization was also associated with a
decrease in microbial evenness (Shannon index) and, within the
non-IC cohort, decreased richness, consistent with findings of
decreased gut microbial diversity in patients with C. difficile
colitis (39, 40).
The non-IC cohort in general and, specifically those who
were not colonized with C. difficile, had higher proportions
of Lachnospiraceae (Roseburia), which are involved in the
production of butyrate. Butyrate is the preferred energy source
of colonic endothelial cells (colonocytes) and plays a major
role in the regulation of colonocyte proliferation and the
differentiation and maintenance of intestinal epithelial integrity
(41). Lachnospiraceae were shown to be partially protective
against C. difficile in murine and human studies (42–44). For
example, in adult allogeneic-HSCT patients, Lachnospiraceae
were associated with a 60% lower risk of C. difficile colitis
independent of other risk factors (44).
There are several limitations to this cross-sectional, single-
center study including the diverse nature of the IC cohort,
lack of longitudinal samples and age differences in the study
populations, particularly comparing children with SCD who
were or were not receiving penicillin prophylaxis. It is also
known that genetic factors including HLA type can influence
the microbial composition, which could account for some of
the differences in the groups (45).Despite these limitations,
the results have generated several hypotheses that should be
addressed in future larger, longitudinal studies. In addition to the
findings that antibiotics and PPIs are associated with decreased
microbial diversity and changes in species composition, the
study uncovered a potentially previously unrecognized patient
population at risk for an altered gut microbiome: children
with SCD, particularly, those receiving penicillin prophylaxis.
Understanding the implications of the observed differences in
the microbiome in this population may have implications for the
future management of patients with SCD.
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Eubacterium rectale, Faecalibacterium prausnitzii, Anaerostipes hadrus and
Eggerthella lenta. ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05, Wilcoxon rank sum test.
Supplementary Figure 2 | Specific species that differentiate the community
composition between patients based on if they were currently on antibiotics (Yes)
or not (No), identified by Random Forest plots: Bacteroides faecis, Paraprevotella
clara, Faecalicatena fissicatena, Roseburia inulinivorans. ∗∗p < 0.01, ∗p < 0.05,
Wilcoxon rank sum test.
Supplementary Figure 3 | Random Forests used to identify specific species
Peptoclostridium difficile, Clostridium spiroforme and Christensenella massiliensis
that differentiate the community composition based on C. difficile colonization
status (Yes) or (No). ∗∗∗∗p < 0.0001, ∗∗∗p < 0.001, ∗p < 0.05, ns, not significant;
Wilcoxon rank sum test.
Supplementary Figure 4 | Random Forests used to identify specific species
Roseburia inulinivorans and Roseburia intestinalis that differentiate the community
composition between IC and non-IC patients based on their C. difficile
colonization status (“C diff” vs. “No C diff”). ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05,
ns, not significant; Kruskal- Wallis test.
Supplementary Figure 5 | Comparison of (A) species richness (OTU count) and
(B) diversity (Shannon index) comparing the SCD (n = 32), IC (without SCD) (n =
37) and non-IC (n = 37) groups. Each point represents an individual patient and
the boxplot shows the median, the first and third quartiles (bottom and top bars of
the boxplot) and minimum and maximum values.
Supplementary Figure 6 | PCoA plot: SCD samples do not cluster differently
from samples in other cohorts.
Supplementary Figure 7 | Random Forests used to identify specific species
(Bacteroides xylanisolvens, Bacteroides fragilis, Clostridium spiroforme and Blautia
obeum) that differentiate the community composition between SCD patients,
based on if they were receiving penicillin prophylaxis (Yes PCN) or not (No PCN).
∗∗p < 0.01,∗p < 0.05, ns, not significant; Wilcoxon rank sum test.
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